Stem Cell Treatment Market size is poised to surpass USD 596 million by the end of 2035, growing at a CAGR of 14% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of stem cell treatment was over USD 263 million. The growth of the market can be attributed to the growing prevalence of chronic diseases such as, cancer, sickle cell disease, lymphoproliferative disorders, tumors, and others. According to WHO, cancer accounted for nearly ten million deaths worldwide in 2020. A study conducted by the International Agency for Research on Cancer 2020 found that approximately 1 in 5 people develops cancer during their lifetime, and about 1 in 8 men and 1 in 11 women die from it. Early diagnosis allows for a more targeted cancer treatment, such as stem cell therapy, which can be more effective than traditional chemotherapy and radiation treatments. Stem cell treatments involve using stem cells to stimulate the body's own immune system to attack cancer cells. The stem cells can also be used to replace damaged cells and restore function to organs that have been damaged by cancer.
In addition to these, other factors that are believed to fuel the market growth of stem cell treatment include the growing demand for regenerative and personalized medicines, and the rise in government funding for stem cell research. Stem cells can be used to create personalized medicines tailored to the individual needs of a patient. Moreover, the ongoing research activities being conducted for the treatment of COVID-19 is expected to further drive market growth in the coming years. For instance, a grant of USD 5 million was awarded to Lineage Cell Therapeutics in May 2020 by the California Institute for Regenerative Medicine (CIRM) to develop a vaccine against SARS-CoV-2, the virus responsible for COVID-19, using VAC, Lineage's allogeneic dendritic cell therapy.
Growth Drivers
Rising Prevalence of Musculoskeletal Disorders Such as Osteoarthritis- According to the World Health Organization (WHO), nearly 1.71 billion people are affected by musculoskeletal conditions worldwide. According to the CDC, one in four US adults (or 54.4 million) suffer from some form of arthritis, with the number projected to rise to 78 million by 2040. The most common form of arthritis, osteoarthritis (OA), affects 32.5 million adults in the US. Stem cell treatment can help to reduce pain, improve mobility and reduce inflammation associated with musculoskeletal disorders. This has led to an increased interest in stem cell treatments as an alternative to traditional treatments such as surgery.
Establishment of New Research and Therapy Center for Stem Cells and Cancer - For instance, a new stem cell and cancer research and therapy center was inaugurated by the Global Institute of Stem Cell Therapy and Research (GIOSTAR) in Chandigarh, India, in February 2020. As part of GIOSTAR's global expansion efforts in India, Mexico, the United States, and other countries, this facility marks the latest milestone. Development of a new center can help drive innovation in the field of stem cell therapy, contributing to more effective treatments and better outcomes.
Increasing Number of Stem Cell-Based Clinical Trials - A preliminary review of 112 stem cell-based clinical trials has been conducted by May 2020. The best results were obtained using hematopoietic stem cells (37%), mesenchymal stem cells (35%), umbilical cord blood (UCB) (23%) and bone marrow (BM)-derived cells (21%).
Availability of Enormous Amounts of Funds for Stem Cell Research and Development- Research funding for stem cells has increased in recent years. Stem cell research is seen as a promising area of medicine, as it could lead to treatments for incurable diseases and injuries. For instance, a funding award of USD 31 million was granted to Stanford Research in September 2021 by the California Institute for Regenerative Medicine for launching first-in-human trials of stem cells for heart failure, strokes, and spinal cord tumours. Also, a Stem Cell SpaceShot Grant in the field of stem cell biology and regenerative medicine has been announced by TreeFrog Therapeutics in April 2022. The grant amounts to USD 100,000 in research funding.
Rise in Approval for Stem Cell Treatments for Type 1 Diabetes (T1D) - For instance, a clinical trial of VX-880 was initiated by Vertex Pharmaceuticals Incorporated in April 2021 after receiving FDA Fast Track Designation in April 2021. The company is testing it on patients with type 1 diabetes (T1D) who suffer from severe hypoglycemia and are unaware of their hypoglycemia. For the treatment of type 1 diabetes, VX-880 uses fully differentiated, insulin-producing pancreatic islet cells derived from stem cells.
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~14% |
|
Base Year Market Size (2022) |
~ USD 263 Million |
|
Forecast Year Market Size (2035) |
~ USD 596 Million |
|
Regional Scope |
|
Treatment Type (Allogeneic, Autologous, Syngeneic)
The global stem cell treatment market is segmented and analyzed for demand and supply by treatment type into allogeneic, autologous and syngeneic. Out of these, the allogeneic segment is estimated to gain the largest market share of about ~43% in the year 2035. The allogeneic segment is gaining popularity owing to its ability to provide long-term benefits for patients, cost effectiveness, and the potential for personalized treatments. Additionally, advancements in stem cell technology and the increasing demand for stem cell therapies are further driving the growth of the allogeneic segment. Moreover, the increasing incidence of blood cancer and genetic disorders are also expected to fuel the segment growth. It is estimated that someone in the US die of a blood cancer every nine minutes. An estimated 57,750 people died from leukemia, lymphoma, and myeloma in the US in 2021. The number of Australians suffering from blood cancer or blood disorders today is around 135,000. Allogeneic stem cell transplant involves harvesting healthy stem cells from a donor and transplanting them into the patient. The healthy stem cells can then proliferate and replace the cancerous cells, allowing the patient to recover from the disease.
Application (Regenerative Medicine, Drug Discovery, Development)
The global stem cell treatment market is segmented and analyzed for demand and supply by application to regenerative medicine and drug discovery and development. Out of these, the regenerative medicine segment is estimated to gain significant market share of about ~57% in the year 2035. The growth of the segment can be attributed to the rising awareness and acceptance of regenerative medicine as regenerative medicine has the potential to revolutionize the healthcare industry by providing treatments for previously untreatable conditions with better outcomes. According to current estimates, regenerative medicine is estimated to potentially have a significant impact on a staggering one out of three Americans. Additionally, advancements in technology have enabled the development of more advanced regenerative medicine treatments that are more effective, faster, and safer. Furthermore, the increasing government funding for regenerative medicine research is expected to lead to further advancements in the field.
Our in-depth analysis of the global market includes the following segments:
|
By Stem Cell Type |
|
|
By Treatment Type |
|
|
By Application |
|
|
By Stem Cell Technology |
|
|
By End User |
|
North American Market Forecast
The market share of stem cell treatment in North America, amongst the market in all the other regions, is projected to be the largest with a share of about ~39% by the end of 2035. The growth of the market can be attributed majorly to the increasing awareness about the potential of stem cell treatments, the rising prevalence of chronic diseases such as diabetes, technological advancements in the field, and the presence of favorable reimbursement policies in the region. According to the Centers for Disease Control and Prevention, a total of 37.3 million people have diabetes (about 11.3% of the US's population). 28.7 million people have been diagnosed, including 28.5 million adults. Stem cell therapy is a promising new therapy for diabetes, as it has the potential to replace the damaged cells that are responsible for producing insulin. This could potentially restore the body's ability to regulate glucose levels and prevent serious complications of diabetes. Additionally, the increased investments by companies for research and development and the rising number of clinical trials related to stem cell treatments are also augmenting the growth of the market.
APAC Market Statistics
The Asia Pacific stem cell treatment market is estimated to be the second largest, registering a share of about ~24% by the end of 2035. The growth of the market can be attributed majorly to the rise of stem cell treatments for a number of diseases, such as cancer, diabetes, and Parkinson's disease, has contributed to increased investment in research and development in the region, as well as increased access to stem cell treatments. Furthermore, researchers in the region have achieved considerable success in the development and implementation of stem cell therapy techniques, which is expected to drive the growth of the stem cell treatment market in the coming years. Stem cell therapy is observed to have a success rate of 65% to 85% in India, which is among the highest in the world. Also, 200 clinical trials for stem cell-based therapies have been enumerated in this study in order to determine the effectiveness of such therapies in China. As stem cell research continues to advance and more successful treatments become available, the potential applications of stem cell therapy continue to expand significantly, providing relief for patients suffering from chronic, degenerative and otherwise incurable diseases. Additionally, the cost of stem cell treatments has decreased significantly in the region owing to the advancements in technology and the availability of more affordable treatments. This has made it more accessible to a larger population.
Europe Market Forecast
Further, the stem cell treatment market in the Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed majorly to the upsurge in number of cell therapy production owing to the growing number of clinical trials and the increasing support from the government and private organizations to fund and promote this type of research. In addition, the increasing number of government initiatives to raise awareness about stem cell treatments is also contributing to the growth of the market. Additionally, technological advancements such as the development of induced pluripotent stem cells (iPSCs) are also contributing to the regional market growth.
A new drug application (IND) has been approved by FDA for Stemedica Cell Technologies, Inc. in order to treat moderate-to-severe COVID-19 with intravenous administration of allogeneic mesenchymal stem cells (MSCs). This new application has shown to be effective in treating the symptoms of moderate-to-severe COVID-19, such as inflammation, fever, and difficulty breathing.
An official announcement from Pluristem Therapeutics Inc. announced that the company's subsidiary, Pluristem Ltd., has signed a non-binding Memorandum of Understanding (MOU) with the Abu Dhabi Stem Cells Center (ADSCC), a special healthcare center for cell therapy and regenerative medicine based in the United Arab Emirates.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?